Skip Content
Page Banner Image

Valbenazine approved by U.S. FDA for treatment of chorea in HD

Neurocrine Biosciences, Inc. announced the U.S. Food and Drug Administration (FDA) has approved INGREZZA ® (Valbenazine) capsules for treatment of adults with chorea associated with Huntington disease (HD) in the United States of America. This approval is supported by data from Neurocrine’s two clinical studies conducted in collaboration with the Huntington Study Group (HSG): the KINECT-HD Phase 3 study and the ongoing KINECT-HD2 open label extension. Please note that Valbenazine is NOT approved for use in Canada, only in an ongoing capacity to study participants. To read more on these studies and Valbenazine please visit:

We would like to highlight the commitment and courage of the HD community members who participate in clinical trials and their families.


Shelly Redman

We support those facing huntington disease
 Latest Blog


Have questions? Send us an email at:



Stay in Touch!
Enter your email address below to receive occasional updates.

Newsletter Sign-up

Copyright © Huntington Society of Canada. All Rights Reserved. Charitable Registration Number 11896 5516 RR0001